Navigation Links
InNexus Biotechnology Announces a Loan Facility of up to USD$2.5 Million
Date:3/25/2009

BRITISH COLUMBIA, Canada, March 25 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology, is pleased to announce that the Company has entered into a loan facility with a group of investors for an aggregate amount of up to USD$2.5 million.

The loan facility, subject to final approval of the TSX, bears interest at 12.5% payable in cash or in Common Shares of InNexus, subject to regulatory approval, and matures 6 months from the date of drawdown. InNexus is entitled to extend the term for a further 6 months. The loans are repayable at any time subject to a 5% penalty. In connection with the loan, InNexus will issue to the lenders at closing common share purchase warrants obtained by a) dividing each lender's loan value by b) the then prevailing market price c) multiplied by 25%. Each warrant will entitle the holder to acquire one common share of InNexus at a price equal to the then prevailing market price, which shall be the same as b), above. The purchase warrants are exercisable for the earlier of a period of 60 months from closing or complete repayment of the loan.

Proceeds of the loan facility are intended to be used for paying current liabilities and operating expenses for InNexus' continued research and development programs.

Concurrently, InNexus announces the resignations of Glenn Williamson and Laurence Luke from the company's Board of Directors, effective March 6, 2009. Chairman Jeff Morhet commented, "I thank Mr. Williamson and Mr. Luke for the work and support of InNexus over the last two years. The entire Board also thanks them for their contribution." Their decision to leave the Company's Board is not based on or reflective of any disagreement related to the Company's operations, policies or practices. The Company does not intend on replacing the Directors at this point and this supports other cost-saving measures.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, which may cause actual results or performance to differ materially from those currently anticipated in such statements.


'/>"/>
SOURCE InNexus Biotechnology Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
2. FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product
3. InNexus Completes Previously Announced Private Placement
4. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
5. InNexus Biotechnology Receives Patent Grants in Europe
6. InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum
7. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
8. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
9. InNexus Biotechnology Strengthens Patent Team With New Leadership
10. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
11. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Research Future has a half cooked research report on Global Liquid ... and expected to reach USD 450 Million by the end of ... ... assessed as a swiftly growing market and expected that the market ... There has been a tremendous growth in the prevalence of cancer ...
(Date:1/19/2017)... , Jan 19, 2017 Research and Markets ... has announced the addition of the ... Application - Forecast to 2025" report to their offering. ... The report provides a detailed analysis on current and future ... till 2025, using estimated market values as the base numbers ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 ... Inc., a privately-held immunotherapeutics company targeting infectious diseases, ... for the merger of PharmAthene and Altimmune in ... Venture Fund, HealthCap, Truffle Capital and Redmont Capital. ... diversified immunotherapeutics company with four clinical stage and ...
(Date:1/19/2017)... ... January 18, 2017 , ... The American Medical Informatics ... its Data Sharing Policy. Specifically, the nation’s leading informatics experts, said data sharing ... existing policy. AMIA recommended that NIH earmark funding for researchers to produce and ...
Breaking Biology Technology:
(Date:12/15/2016)... Canada and BADEN-BADEN, Germany , ... a leading global financial services provider, today announced an agreement ... passive behavioural biometrics, to join forces. The partnership will enable ... mitigation strategies in compliance with local data protection regulation. ... In order ...
(Date:12/15/2016)... , Dec. 15, 2016  There is much ... doors or starting the engine. Continental will demonstrate the ... Las Vegas . Through the combination of ... and Entry) and biometric elements, the international technology company ... vehicle personalization and authentication. "The integration of ...
(Date:12/8/2016)...  Singulex, Inc., the leader in Next Generation Immunodiagnostics ... license and supply agreement with Thermo Fisher Scientific, the ... access to Thermo Scientific BRAHMS PCT (Procalcitonin), a biomarker ... to diagnose systemic bacterial infection and sepsis and in ... in assessing the risk of critically ill patients for ...
Breaking Biology News(10 mins):